Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H27N.ClH |
| Molecular Weight | 353.928 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(CC1=CC=C(C=C1)C(C)(C)C)CC2=C3C=CC=CC3=CC=C2
InChI
InChIKey=LJBSAUIFGPSHCN-UHFFFAOYSA-N
InChI=1S/C23H27N.ClH/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20;/h5-15H,16-17H2,1-4H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C23H27N |
| Molecular Weight | 317.4672 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Butenafine is a synthetic antifungal agent that is structurally and pharmacologically related to allylamine antifungals. The exact mechanism of action has not been established, but it is suggested that butenafine's antifungal activity is exerted through the alteration of cellular membranes, which results in increased membrane permeability, and growth inhibition. Butenafine is mainly active against dermatophytes and has superior fungicidal activity against this group of fungi when compared to that of terbinafine, naftifine, tolnaftate, clotrimazole, and bifonazole. It is also active against Candida albicans and this activity is superior to that of terbinafine and naftifine. Butenafine also generates low MICs for Cryptococcus neoformans and Aspergillus spp. as well. Butenafine hydrochloride is marketed under the trade names Mentax, Butop (India) and is the active ingredient in Lotrimin Ultra. MENTAX Cream, 1%, is indicated for the topical treatment of tinea (pityriasis)
versicolor due to Malassezia furfur (formerly Pityrosporum orbiculare). Although the mechanism of action has not been fully established, it has been suggested that butenafine, like allylamines, interferes with sterol biosynthesis (especially ergosterol) by inhibiting squalene monooxygenase, an enzyme responsible for converting squalene to 2,3-oxydo squalene. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Blockage of squalene monooxygenase also leads to a subsequent accumulation of squalene. When a high concentration of squalene is reached, it is thought to have an effect of directly kill fungal cells. Butenafine cream 1% is indicated in treatment of tinea
pedis, tinea corporis and tinea cruris. In tinea pedis it is
recommended twice daily for 7 days or once daily for
4 weeks. In tinea cruris and tinea corporis it is recommended
once daily for two weeks.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL366 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8494375 |
|||
Target ID: CHEMBL613162 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11516941 |
|||
Target ID: CHEMBL612926 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | MENTAX Approved UseMENTAX-TC Cream, 1%, is indicated for the topical treatment of tinea (pityriasis)
versicolor due to Malassezia furfur (formerly Pityrosporum orbiculare). Launch Date1996 |
|||
Sources: https://www.drugs.com/ppa/butenafine.html |
Primary | Butenafine Approved UseOTC labeling: Topical treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) Launch Date1996 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.4 ng/mL |
6 g 1 times / day multiple, topical dose: 6 g route of administration: Topical experiment type: MULTIPLE co-administered: |
BUTENAFINE blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
5 ng/mL |
20 g 1 times / day multiple, topical dose: 20 g route of administration: Topical experiment type: MULTIPLE co-administered: |
BUTENAFINE blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
23.9 ng × h/mL |
6 g 1 times / day multiple, topical dose: 6 g route of administration: Topical experiment type: MULTIPLE co-administered: |
BUTENAFINE blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
87.8 ng × h/mL |
20 g 1 times / day multiple, topical dose: 20 g route of administration: Topical experiment type: MULTIPLE co-administered: |
BUTENAFINE blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
35 h |
20 g 1 times / day multiple, topical dose: 20 g route of administration: Topical experiment type: MULTIPLE co-administered: |
BUTENAFINE blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| [Activity of butenafine against ocular pathogenic filamentous fungi in vitro]. | 2010-01 |
|
| Simultaneous HPLC determination of butenafine hydrochloride and betamethasone in a cream formulation. | 2009-09 |
|
| Update on terbinafine with a focus on dermatophytoses. | 2009-04-21 |
|
| In vitro antifungal activities of luliconazole, a new topical imidazole. | 2009 |
|
| Fungal toenail infections. | 2008-12-15 |
|
| Are placebo-controlled trials of creams for athlete's foot still justified? | 2008-09 |
|
| Butenafine and superficial mycoses: current status. | 2008-07 |
|
| Randomised controlled trial of topical butenafine in tinea cruris and tinea corporis. | 2007-07-24 |
|
| Topical treatments for fungal infections of the skin and nails of the foot. | 2007-07-18 |
|
| An unprecedented rearrangement in collision-induced mass spectrometric fragmentation of protonated benzylamines. | 2006-09 |
|
| [The effect of propyl gallate on the activity of various antifungal drugs against filamentous fungi in vitro]. | 2006-04 |
|
| What is the best way to treat tinea cruris? | 2006-03 |
|
| In vitro antifungal activity of ZJ-522, a new triazole restructured from fluconazole and butenafine, against clinically important fungi in comparison with fluconazole and butenafine. | 2005-08 |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005-06 |
|
| Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: a randomized, double-blind trial. | 2005 |
|
| Topical therapy for fungal infections. | 2004 |
|
| Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. | 2003-09 |
|
| Butenafine: an update of its use in superficial mycoses. | 2002-09 |
|
| A Japanese case of tinea corporis caused by Arthroderma benhamiae. | 2002-04 |
|
| KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs. | 2002 |
|
| Six novel antimycotics. | 2002 |
|
| Experimental and conformational analyses of interactions between butenafine and lipids. | 2001-12 |
|
| Comparison of in vitro antifungal activities of topical antimycotics launched in 1990s in Japan. | 2001-08 |
|
| Efficacy and safety of butenafine in superficial dermatophytoses (tinea pedis, tinea cruris, tinea corporis). | 2001-05 |
|
| Butenafine hydrochloride (Mentax) cream for the treatment of hyperkeratotic type tinea pedis and its transfer into the horny layer, with or without concomitant application of 20% urea ointment (Keratinamin). | 2001 |
|
| Butenafine hydrochloride: for the treatment of interdigital tinea pedis. | 2000-03 |
|
| Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis. | 1998-06 |
|
| Butenafine. | 1998-03 |
|
| Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment. | 1993-07-23 |
|
| Two mechanisms of butenafine action in Candida albicans. | 1993-04 |
|
| [Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent]. | 1991-02 |
Sample Use Guides
Patients with tinea (pityriasis) versicolor should apply MENTAX-TC Cream, 1% (Butenafine), once daily for seven days. Sufficient MENTAX-TC Cream, 1%, should be applied to cover affected areas and
extending 4 inches (10.2 cm) onto normal skin immediately surrounding the affected area.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12895182
Butenafine HCl shows minimum inhibitory concentrations ranging from 0.03–1.0 ug/mL against 30 isolates representing different dermatophyte species.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:13:46 GMT 2025
by
admin
on
Mon Mar 31 18:13:46 GMT 2025
|
| Record UNII |
R8XA2029ZI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB00914MIG
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
DBSALT000245
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
R8XA2029ZI
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
DTXSID2048589
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
II-94
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
31325
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
443867
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
C47426
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
100000084840
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
CHEMBL990
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
101827-46-7
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
R8XA2029ZI
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | |||
|
m2791
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | Merck Index | ||
|
236558
Created by
admin on Mon Mar 31 18:13:46 GMT 2025 , Edited by admin on Mon Mar 31 18:13:46 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |